AcuCort

AcuCort EBITDA per Employee

The EBITDA per Employee of AcuCort (ACUC.SL) as of Oct 16, 2026 is -3.43 M SEK. In the previous year, EBITDA per Employee was -3.31 M SEK — a change of 3.49% (lower).

EBITDA per Employee

-3.43 MSEK

YoY

3.49%

Last updated:

EBITDA per Employee of AcuCort is 2024 -3.43 M SEK. EBITDA per Employee of AcuCort was 2023 -3.31 M SEK. It decreases by 3.49% lower compared to the previous year.

The AcuCort EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2017
-1.17 M SEK
Jan 1, 2018
-1.56 M SEK
Jan 1, 2019
-2.09 M SEK
Jan 1, 2020
-1.94 M SEK
Jan 1, 2021
-2.82 M SEK
Jan 1, 2022
-3.71 M SEK
Jan 1, 2023
-3.31 M SEK
Jan 1, 2024
-3.43 M SEK
The AcuCort EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-3.43 MSEK+3.49%
-3.31 MSEK-10.63%
-3.71 MSEK+31.25%
-2.82 MSEK+45.77%
-1.94 MSEK-7.43%
-2.09 MSEK+34.54%
-1.56 MSEK+33.26%
-1.17 MSEK+143.20%
-479,925.00SEK-11.90%
-544,775.00SEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

AcuCort Stock analysis

What does AcuCort do? AcuCort AB is a pharmaceutical company based in Lund, Sweden, operating within the Health Care sector. The company focuses on the development, marketing, and sale of oral dissolvable films, specifically targeting medical applications. Its primary product, ISICORT, utilizes dexamethasone, a glucocorticoid, for treating acute allergic reactions and managing nausea and vomiting associated with chemotherapy. AcuCort AB has a small operational footprint, employing four full-time staff members. The company completed its initial public offering (IPO) on April 24, 2017, and is listed under the ticker ACUC.SL with ISIN SE0009695927. It maintains a website at https://acucort.se/ for further information. AcuCort AB operates predominantly in the Nordic region, with its headquarters situated in Lund, Skåne. The company's business model centers on the production and distribution of specialized pharmaceutical products designed to address specific medical needs. While details about its financial performance, market share, or additional product lines are not provided, the company's focus remains on its core product and regional market presence. Its operational scale reflects a startup or early-stage pharmaceutical enterprise with limited resources. The company's website serves as the primary source for updates and corporate information. AcuCort AB's activities are confined to the development and commercialization of oral film technology, emphasizing targeted therapeutic applications in healthcare. AcuCort is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AcuCort stock

EBITDA per Employee of AcuCort is -3.43 M SEK in 2024.

EBITDA per Employee of AcuCort changed from -3.31 M SEK to -3.43 M SEK, representing a 3.49% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee AcuCort since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's AcuCort historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Workforce — AcuCort

EmployeesRevenue per EmployeeProfit per EmployeeMarket Cap per EmployeeEBIT per EmployeeEBITDA per EmployeeR&D per EmployeePP&E per Employee

All Key Metrics — AcuCort